Recruitment in Acute Stroke Trials: Challenges and Potential Solutions

Joseph P. Broderick*, Yasmin N. Aziz, Opeolu M. Adeoye, James C. Grotta, Andrew M. Naidech, Andrew D. Barreto, Colin P. Derdeyn, Heidi J. Sucharew, Jordan J. Elm, Pooja Khatri

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Randomized clinical trials of acute stroke have led to major advances in acute stroke therapy over the past decade. Despite these successes, recruitment in acute trials is often difficult. We outline challenges in recruitment for acute stroke trials and present potential solutions, which can increase the speed and decrease the cost of identifying new treatments for acute stroke. One of the largest opportunities to increase the speed of enrollment and make trials more generalizable is expansion of inclusion criteria whose impact on expected recruitment can be assessed by epidemiologic and registry databases. Another barrier to recruitment besides the number of eligible patients is availability of study investigators limited to business hours, which may be helped by financial support for after-hours call. The wider use of telemedicine has accelerated quicker stroke treatment at many hospitals and has the potential to accelerate research enrollment but requires training of clinical investigators who are often inexperienced with this approach. Other potential solutions to enhance recruitment include rapid prehospital notification of clinical investigators of potential patients, use of mobile stroke units, advances in the process of emergency informed consent, storage of study medication in the emergency department, simplification of study treatments and data collection, education of physicians to improve equipoise and enthusiasm for randomization of patients within a trial, and clear recruitment plans, and even potentially coenrollment, when there are competing trials at sites. Without successful recruitment, scientific advances and clinical benefit for acute stroke patients will lag.

Original languageEnglish (US)
Pages (from-to)632-638
Number of pages7
JournalStroke
Volume54
Issue number2
DOIs
StatePublished - Feb 1 2023

Funding

Dr Broderick reports study medication supplies from Novo Nordisk for ongoing NINDS-funded FASTEST Trial. Department of Neurology receives monies to an educational/research fund from Genentech for his role on Executive Committee of Timeless Trial; from Roche Pharmaceuticals for consulting, from BrainsGate Ltd for consulting; from Basking Biosciences, from Kroger Prescription Plans, Inc’s Pharmacy &Therapeutics Committee as voting member of committee. Dr Grotta reports research grant support from Genentech, CSL Behring, Chiesi. Chair of DSMB for Prolong Pharma sponsored trial of Humera. U.S. P.I. of Acticor Corp trial of Glenzocimab. Consultant to Haemonetics, BrainsGate, Frazer Ltd. Dr Adeoye: Sense Diagnostics, Inc - Founder and Equity Holder. Nico Corp - DSMB Member. Dr Khatri reports grant from Johnson & Johnson Health Care Systems Inc. (ENDOLOW trial Multiple Principle Investigator); personal fees from Bayer (Bayer-PACIFIC trial national leader), Lumosa (DSMB and scientific advisory board), Basking Biosciences (scientific advisory board), and Diamedica (scientific advisory board); and royalties from UpToDate, Inc. Dr Derdeyn reports research grant support from Siemens Healthineers; Pulse Therapeutics – Equity; Penumbra, Inc – DSMB Chair for MIND trial, DSMB member for THUNDER trial; Silkroad, Inc – DSMB chair, NITE trial; NoNO, Inc – DSMB Chair ESCAPE-Na1 and FRONTIER trials. The other authors report no conflicts.

Keywords

  • data collection
  • financial support
  • informed consent
  • stroke
  • telemedicine

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Fingerprint

Dive into the research topics of 'Recruitment in Acute Stroke Trials: Challenges and Potential Solutions'. Together they form a unique fingerprint.

Cite this